BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gamgertamig (CM336) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gamgertamig (CM336)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07083960-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gamgertamig (CM336): Phase 1 readout est. (NCT07083960)
DESCRIPTION:Gamgertamig (CM336)\, phase 1.\nStudy: OM336 in Autoimmune Cyto
 penias\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07083960
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05299424-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT05299424)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2\, Multiple Myeloma.\nStudy: A S
 tudy of CM336 in Patients With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05299424
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115667-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07115667)
DESCRIPTION:Gamgertamig (CM336)\, phase 2.\nStudy: Radiation Combined With 
 BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With M
 ild Bone Marrow Infiltration\nEstimated primary completion: 1 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0711
 5667
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115654-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07115654)
DESCRIPTION:Gamgertamig (CM336)\, phase 2.\nStudy: BCMA/CD3 BsAb Therapy fo
 r POEMS Syndrome\nEstimated primary completion: 1 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07115654
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06900010-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT06900010)
DESCRIPTION:Gamgertamig (CM336)\, phase 2.\nStudy: A Study to Evaluate CM33
 6 in Adults With Autoimmune Bullous Disease\nEstimated primary completion:
  1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gamg
 ertamig-cm336#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06900010
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407010-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Gamgertamig (CM336): Phase 1 readout est. (NCT07407010)
DESCRIPTION:Gamgertamig (CM336)\, phase 1\, Multiple Myeloma.\nStudy: BCMA/
 CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in 
 RRMM\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07407010
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229144-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gamgertamig (CM336): Phase 1 readout est. (NCT07229144)
DESCRIPTION:Gamgertamig (CM336)\, phase 1.\nStudy: OM336 in Seropositive Au
 toimmune Diseases\nEstimated primary completion: June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07229144
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648459-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07648459)
DESCRIPTION:Gamgertamig (CM336)\, phase 2\, Multiple Myeloma.\nStudy: CM336
 -SOC for Dynamically High-Risk Multiple Myeloma Study\nEstimated primary c
 ompletion: 9 July 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gamgertamig-cm336#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07648459
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687004-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT07687004)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2\, Multiple Myeloma.\nStudy: Son
 rotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amylo
 idosis Based on t(11\;14) Genetic Stratification\nEstimated primary comple
 tion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 gamgertamig-cm336#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07687004
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745687-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Gamgertamig (CM336): Phase na readout est. (NCT06745687)
DESCRIPTION:Gamgertamig (CM336)\, phase na\, Multiple Myeloma.\nStudy: BCMA
 /CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma\nEstim
 ated primary completion: 1 August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06745687
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181239-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07181239)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336 in Relapsed or Refractory Multiple Myeloma Patients\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07181239
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175493-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT07175493)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2.\nStudy: A Study of CM336 in Pa
 tients With Relapsed or Refractory Autoimmune Cytopenia\nEstimated primary
  completion: 18 November 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07175493
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642843-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Gamgertamig (CM336): Phase 1 readout est. (NCT07642843)
DESCRIPTION:Gamgertamig (CM336)\, phase 1.\nStudy: CM336 for Active Sjogren
 's Syndrome Study\nEstimated primary completion: April 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07642843
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585760-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07585760)
DESCRIPTION:Gamgertamig (CM336)\, phase 2\, Multiple Myeloma.\nStudy: CM336
  Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairmen
 t\nEstimated primary completion: 1 May 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07585760
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830485-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20290415
DTEND;VALUE=DATE:20290416
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07830485)
DESCRIPTION:Gamgertamig (CM336)\, phase 2\, Multiple Myeloma.\nStudy: CM336
  Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnose
 d Multiple Myeloma\nEstimated primary completion: 15 April 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07830485
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652905-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07652905)
DESCRIPTION:Gamgertamig (CM336)\, phase 2.\nStudy: CM336 Plus Isa-VR in New
 ly Diagnosed Primary Plasma Cell Leukemia\nEstimated primary completion: 3
 0 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gamgerta
 mig-cm336#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07652905
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910903-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07910903)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07910903
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789431-3157@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07789431)
DESCRIPTION:Gamgertamig (CM336)\, phase 2.\nStudy: OM336 in Sensitized Tran
 splant Candidates\nEstimated primary completion: 1 July 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07789431
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
